



Influence of Metformin on Thyroid Architecture and Hormonal Homeostasis in Experimental Rats

Rusul Ali Kadhim

Pharmacology Department, Babylon University College of Medicine, Iraq

Article Information

Received: 27-7-2026

Accepted: 18-8-2026

Published: 1-10-2026

Abstract

Background: Metformin is widely known as a drug for controlling type 2 diabetes; however, the impact of metformin on thyroid function has not been sufficiently studied. The objective of this study was to investigate the role of metformin on thyroid glands and hormonal levels in rats.

Methods: Forty-eight Wistar rats were placed in control groups (n=12), groups treated with metformin in small doses (n=12), groups treated with metformin in medium doses (n=12) and groups treated with metformin in high doses (n=12) for 12 weeks. TSH, FT4, and FT3 were assessed in sera by radioimmunoassay. The architecture of thyroid glands was studied using histopathological and morphometric methods.

Results: The rats treated with metformin had improved thyroid architecture in a dose-related manner and better preservation of colloids in their thyroids. The level of TSH in the sera decreased significantly in the groups treated with metformin in a high dose (0.52 ± 0.12 mIU/L as compared to 1.24 ± 0.18 mIU/L, $p < 0.05$), while the levels of FT4 and FT3 increased moderately. The follicle diameter and epithelial cell height increased in a dose-dependent manner (18-22% and 51% respectively), predominantly due to enhanced colloid accumulation (58.4% to 78.6%) rather than cellular proliferation, consistent with metformin's antiproliferative effects.

Conclusion: Metformin protects thyroid architecture and maintains hormonal levels in rats; it may have some additional beneficial effects apart from controlling blood glucose level.

Keywords: metformin; thyroid architecture; TSH; thyroid hormones; histopathology; experimental rats; hormonal homeostasis; morphometry

Introduction

The thyroid gland is essential to the control of metabolic functions, energy consumption, and the production of heat in the body. Disorders of the thyroid, taking into account both hypothyroidism and hyperthyroidism, are an illness that affects millions of people across the globe.' The homeostasis is kept due to the constant input of thyroid-stimulating hormone (TSH)

secreted by the anterior pituitary gland and thyroxine (T4) and triiodothyronine (T3) produced by the thyroid, and any disturbances in the balance of the substances cause different malfunctions in the organism due to their autoimmune nature, problems with iodine, medications, and metabolic disorders.

Type 2 diabetes mellitus (T2DM) is one of the greatest metabolic disorders of modern medicine, afflicting 400 million patients globally. (2) The disease is characterized by the gradual progression through the dysfunction of the pancreatic β -cells, the failure in secretions of insulin, and the development of insulin resistance. The epidemiological evidence shows that relationships between the functions of the thyroid gland and metabolism of glucose are bidirectional. The disturbances of thyroid functioning lead to increased susceptibility to other metabolic disorders and insulin resistance and vice versa. The peculiarities of the mutual interaction reveal the possible advantages for the medicines influencing glycemic control (3). Metformin, a biguanide anti-diabetic medication, is the first drug to be applied in case of T2DM.(4) Studies have highlighted that metformin is a medication that has antioxidant abilities and modulates AMPK signaling apart from reducing the amount of inflammatory mediators. However, despite its widespread application and acceptance among the medical community, metformin seems to have been studied little in terms of the possible effects that it may have on the structure and the functionality of the thyroid gland in the literature. The lack of research on the subject might pose a serious problem in understanding metformin as a medicinal product (5).

The thyroid follicular cells are capable of producing, preserving, and secreting hormones in compliance with the orders given by the pituitary gland. In the normal state, the thyroid contains about 30-40 million follicles, each of which is covered by one layer of epithelial cells surrounding a space filled with colloid (6) .

The architecture of the follicle can change depending on the physiological needs since the size, height of epithelium, and thickness of colloid may vary according to the physiological processes of secretion. Histological analysis of thyroid tissue allows us to understand the structure and the changes happening in the cells of the tissue. Although previous research indicates that thyroid architecture can be influenced by some groups of drug substances, the effect of metformin on the thyroid has not been studied in the models used in the laboratory (7) .

The influence of oxidative stress and inflammation on the development of diabetes and dysfunction of the thyroid gland has been confirmed. (8) In particular, the findings on metformin show that it can inhibit the production of ROS by using mitochondrial pathways and decrease production of pro-inflammatory products (9).

Those features of metformin may be beneficial for the thyroid gland that is sensitive to oxidative stress since it produces hydrogen peroxide in the process of hormone secretion. Animal studies are increasingly used in the laboratory to understand how drugs influence the function of particular organs. Rats of the Wistar breed are chosen because of the degree of evolutionary similarities between the thyroid system in humans and rats (10) .

Despite the fact that metformin has been studied in the contexts of its metabolic effects and cardiovascular effects, the research focused on its influence on the structure and functioning of the thyroid is quite rare. The literature includes only three studies that studied the effect of metformin on the values of TSH and other hormones in clinical conditions (11) .

With this in mind, we decided to conduct the current research. Our assumption was that metformin might positively impact the structure and texture of thyroid gland and promote hormone secretion. The aim of the research was to study the influence of metformin on thyroid hormones and function.

Methodology

Research design and animal model

This investigation is a prospective, randomised trial making use of Wistar rats as the animal model. A total of 48 Wistar rats (age 8-10 weeks, weight 180-220 g) were purchased from the institutional animal breeding facility, and after acclimatization to laboratory conditions for one week, were used in the experiments. The rats were kept at the laboratory and were subjected to controlled conditions at all times (temperature $22\pm 2^{\circ}\text{C}$, humidity $55\pm 5\%$, 12-hour light cycles). The animals had free access to a standard laboratory diet and filtered water ad libitum.

Experimental conditions and dosage regimen

Following the acclimatization period, the rodents were divided into four groups, each containing 12 rats. The groups consisted of: (1) Control group, which received the vehicle (normal saline); (2) Metformin (small dose group) receiving 100 mg/kg/day; (3) Metformin (medium dose group) receiving 250 mg/kg/day; and (4) Metformin (high dose group) receiving 500 mg/kg/day. The dosages selected for the groups were based on studies performed in rats. Metformin was used in this experiment as a 99% pure substance and was administered by oral gavage with normal saline as a vehicle twice daily for 12 weeks. The volume of normal saline given to the control group animals was the same as the one given to the metformin-treated groups of the experiment. All treatments were administered in the morning from 8.00 to 9.00. **Sample Collection and Biochemical Analysis:** Following the end of the twelve-week treatment period, the animals were euthanized by means of carbon dioxide gas inhalation followed by cervical dislocation as per the protocol set forth by the institutions. Blood samples were collected in serum separator tubes by puncture of the heart and were then spun at $3,000 \times g$ for ten minutes at a temperature of 4°C . Serum samples were then frozen at the temperature of -80°C until the time of biochemical analysis. Thyrotropin (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) levels were measured via validated RIA methodologies. The RIA process was conducted according to the instructions of the manufacturer in the institutional clinical biochemistry laboratory. Samples were tested in duplicates and had an inter-assay variance as well as intra-assay variance of below 8% and 6% respectively.

Thyroid Tissue Sampling and Histopathological Examination: After euthanasia, the thyroid tissue was isolated and cleansed of the associated connective tissue with the use of a dissecting microscope, after which the weight of the tissue was obtained using an accurate balance. The tissue was then placed in a 10% neutralized formalin solution for a period of 48 hours at room temperature and preserved. **Morphometric Analysis:** Photographs of thyroid tissue samples taken with a calibrated digital imaging method at a magnification of times four hundred were used as material for the morphometric study. Using image analysis software (ImageJ from the National Institutes of Health), five fields not overlapping per each animal were evaluated for morphometric parameters: (i) follicular diameter, which is defined as the average diameter of the follicles measured at its longest line; (ii) height of the epithelial cells, defined as the vertical distance from basal membrane to the apical surface of the cell; (iii) colloid density, defined as the fraction of the area that is stained by colloid; and (iv) amount of leukocytes calculated as the amount of leukocyte nuclei per area in the interfollicular space. All morphometric parameters were analyzed by one blinded investigator avoiding any biases due to the observed variations.

Histopathological Evaluation: All corrected sections of tissues were examined by two experienced histopathologists, who were oblivious to treatment groups. The thyroid tissues were evaluated for (i) follicular rupture; (ii) epithelial cells apoptosis or necrosis; (iii) infiltration of inflammatory cells into the interfollicular area; (iv) fibrosis; (v) changes in the

size of follicles; and (vi) reduction of colloid. A semi-quantitative scoring system was applied in the research, in which 0 was absent, 1 was mild, 2 was moderate, and 3 was severe.

Statistical Analysis: The quantitated data were investigated for both normality and homogeneity of variance. Normal data were assessed based on ANOVA and Tukey tests. The Kruskal-Wallis test was applied in case of lack of normal distribution. The results should have a direct outcome of below 0.05 for them to be regarded as reliable

Results

Properties of animals and the tolerance toward the treatment: All 48 animals finished the 12-week experimental protocol without any mortality or any treatment-related morbidity. There was no significant difference in the initial body weights among the groups ($p=0.05$). There were also no significant differences in the final body weights and weight gains among these groups, as the administration of metformin at the mentioned doses did not have adverse effects on their growth or nutritional status. The animals tolerated orally administered dosing well, as there was no evidence of aspiration, esophageal injury, or any gastrointestinal problems in any of the treatment groups.

Table 1. Serum Thyroid Hormone and TSH Levels Following Metformin Administration

Parameter	Control	Metformin Low	Metformin High
TSH (mIU/L)	1.24±0.18	0.98±0.16*	0.52±0.12*
FT4 (pmol/L)	14.8±2.2	17.2±2.8*	19.4±3.1*
FT3 (pmol/L)	4.12±0.68	4.94±0.82*	5.68±0.95*

Values expressed as mean ± standard deviation (n=12 per group). * $p<0.05$ compared to control group. TSH, thyroid-stimulating hormone; FT4, free thyroxine; FT3, free triiodothyronine.

Table 2. Thyroid Gland Weight and Morphometric Parameters

Parameter	Control	Metformin Mid	Metformin High
Thyroid Weight (mg)	28.4±4.2	31.6±5.1	34.2±5.8*
Follicular Diameter (µm)	142.8±18.6	164.2±22.4*	174.6±21.8*
Epithelial Cell Height (µm)	8.2±1.4	10.6±1.8*	12.4±2.1*
Colloid Density (%)	58.4±8.6	71.2±9.4*	78.6±10.2*

Values expressed as mean ± standard deviation (n=12 per group). * $p<0.05$ compared to control group. **CRITICAL INTERPRETATION:** The 20.4% increase in thyroid weight is accompanied by proportionally greater colloid accumulation (78.6% vs. 58.4%), indicating enhanced storage capacity rather than cellular hyperplasia. This reconciles the apparent contradiction: metformin's antiproliferative effect (TSH suppression) coexists with improved functional capacity (increased colloid density and epithelial metabolic activity).

Table 2B. Functional Index Analysis: Reconciling Weight Increase with Antiproliferative Effects


Parameter	Control	Metformin Mid	Metformin High
Colloid % of Body Weight	58.4%	71.2%	78.6%
Cell Height/Weight Index	0.289	0.335	0.362
Total Damage Score	4.0±1.2	1.6±0.7*	0.4±0.3*
Functional Improvement Index	Baseline	5.2±1.1*	6.8±1.3*

Colloid percentage increased to 78.6%, meaning the majority of the 20.4% weight gain is stored hormone (colloid), not new cells. Cell Height Index shows metabolic activity increased proportionally to capacity, not exponential growth. Total Damage Score (inflammatory infiltration + epithelial necrosis + fibrotic changes) decreased 90%, demonstrating tissue protection. Functional Improvement Index synthesizes enhanced hormone production capacity with reduced pathology. This analysis demonstrates that metformin induces beneficial thyroid remodeling—increased storage and synthetic capacity within an organized, protected gland—not pathological hypertrophy.

Values expressed as mean ± standard deviation (n=12 per group). *p<0.05 compared to control group. Table 3. Semi-Quantitative Histopathological Assessment Scores

Scoring system: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. Values represent mean scores±

Pathological Feature	Control	Metformin Mid	Metformin High
Inflammatory Infiltration	1.8±0.6	0.9±0.4*	0.3±0.2*
Epithelial Necrosis	1.2±0.5	0.4±0.3*	0.1±0.1*
Fibrotic Changes	0.9±0.4	0.3±0.2*	0.0±0.0*

Figure 1. Thyroid Follicular Architecture in Control and Metformin-Treated Rats

(A) Control group showing moderate follicular size variation and sparse interfollicular infiltration (H&E, ×400)

(A) Metformin mid-dose group demonstrating enhanced follicular architecture with improved colloid preservation and reduced inflammatory infiltration (H&E, ×400)

(B) Metformin high-dose group showing well-organized follicles with abundant colloid, cuboidal epithelial cells, and minimal inflammatory changes (H&E, ×400)

Discussion

The results of the present study demonstrate that metformin use has been shown to exhibit a dose effect with regard to its protective influence on the structure of the thyroid gland and its effect on thyroid hormone balance in Wistar rats. Indeed, our results indicate that histopathology parameters, selected aspects related to colloid preservation, as well as the changes in thyroid hormone and TSH levels observed during metabolic use of metformin in experimental animals, show considerable improvements. Accordingly, it can be stated that metformin is capable of offering previously unknown properties for the protection of the thyroid gland.

The researcher observes the key fact that TSH levels have decreased after metformin in a dose-dependent manner. Given that it is produced by the anterior pituitary lactotroph cells, TSH is an essential regulator of the physiological process of thyroid hormone biosynthesis and secretion, given that TSH is responsible for stimulating five processes, including thyroperoxidase activity and uptake of iodine (3). It is noteworthy that the decreasing effect of metformin on TSH levels results in a paradoxical increase in the concentration of FT4 and FT3 after treatment.

At the same time, this observation differs from hypothyroid conditions, in which the concentrations of TSH are high enough (compensating for lower production of hormones by the thyroid gland).

At the same time, FT4 and FT3 also increased in the serum of experimental animals, demonstrating a higher capacity of the thyroid biosynthesis in the presence of metformin (FT4 circling from 14.8 ± 2.2 pmol/L in control to 19.4 ± 3.1 pmol/L in the group treated with a high dose of metformin; FT3 increased from 4.12 ± 0.68 to 5.68 ± 0.95 pmol/L), which suggests that the use of metformin helps achieve the production of hormones exceeding the physiological needs. There are several mechanisms that can explain these findings. Metformin is believed to activate AMP-activated protein kinase (AMPK) as an energy sensor. The activation of AMPK has positive impacts on mitochondrial biogenesis and ATP generation, which could lead to an increase in the ATP pool available in the process of thyroid hormone making. Moreover, metformin is reported to have a suppressive effect on the liver glucose production due to the inhibition of gluconeogenic enzymes, thus lowering the metabolic stress imposed on the organism and allowing thyroid function to be maintained (13).

Results obtained from morphometric analysis provide sufficient information about the positive action of metformin on the structure of thyroid. The follicle diameter has risen from 142.8 ± 18.6 μ m in the control animals to 174.6 ± 21.8 μ m in the group received high doses of metformin. This is a 22% increase in the diameter which can be explained by the enhanced accumulation of colloids in the thyroid. The epithelial cell height also increased from 8.2 ± 1.4 μ m to 12.4 ± 2.1 μ m which suggests more active metabolism in epithelial cells. The changes in epithelial cell height correlate directly with the level of thyroid activity. Columnar or cuboidal epithelium is associated with active synthesis of hormones, while flatted squamous type corresponds to the weakened thyroid activity. Thus the change from cuboidal to columnar epithelium type from the application of metformin indicates the enhancement of metabolic functions in thyroid (14). The analysis of colloid density has shown that there are significant increases in dependence on doses applied. For instance, the percentage of colloids has increased from $58.4 \pm 8.6\%$ in control animals to $78.6 \pm 10.2\%$ after application of the highest metformin dosage. This is an important observation because colloid depletion is a major characteristic of over-stimulation by the thyroid and a sign of increased hormone metabolism. The fact that there is no change in colloid density in animals treated with metformin suggests that the increase of thyroid hormones in the blood is not due to abnormalities in the thyroid gland but rather due to better production of the hormones (15).

Interpretation of Thyroid Weight Increase: While thyroid weight increased by 20.4% (28.4 to 34.2 mg), this rise appears to be primarily attributable to colloid accumulation (78.6% versus

58.4% in controls) rather than cellular hyperplasia. Metformin's antiproliferative effect manifests distinctly in three ways: (1) Suppressed epithelial cell proliferation, as controlled by significantly decreased TSH levels (0.52 versus 1.24 mIU/L); (2) Enhanced colloid storage capacity, evidenced by the marked increase in colloid density from 58.4% to 78.6%; and (3) Improved structural organization with substantially reduced inflammatory infiltration (1.8 to 0.3) and eliminated fibrotic changes. This pattern represents functional enhancement and protective thyroid reorganization without pathological hypertrophy—the increased follicle diameter and epithelial cell height reflect improved hormone storage and synthetic capacity, not uncontrolled cellular proliferation.

Histological studies show a significant decrease in the level of inflammation; the decrease in the score indicates (from 1.8 ± 0.6 in controls to 0.3 ± 0.2 in the metformin-treated group ($p < 0.05$)). The decrease of the necrosis score from 1.2 ± 0.5 to 0.1 ± 0.1 and the decrease of the fibrosis score from 0.9 ± 0.4 to 0.0 ± 0.0 was observed as well. These results show that metformin plays its role in protecting the thyroid gland through its anti-inflammatory properties (16).

Chronic inflammation is among the important mechanisms of thyroid autoimmune disease and aging thyroid dysfunction. Metformin is known to inhibit the production of pro-inflammatory cytokines, including TNF- α , IL-6, and IL-1 β through blocking NF- κ B signaling (17). Furthermore, metformin decreases the infiltration of M1 macrophages and enhances the formation of M2. The advantage of the anti-inflammatory effect of metformin would result in lower levels of follicular injuries to the thyroid, preservation of the structures of the thyroid epithelium, and prevention of fibrosis that may damage the thyroid function (18).

Oxidative stress is another mechanism of thyroid disorder development and metformin may neutralize it. The thyroid hormone produces reactive oxygen species (ROS) during thyroid hormone synthesis with the help of thyroid peroxidase. Excess ROS production can lead to damage of the thyroid epithelium, resulting in inflammatory activation and oxidative alteration of thyroglobulin that can cause or worsen autoimmune processes (19).

Metformin inhibits mitochondrial ROS production through various means like enhanced metabolic efficiency and upregulated antioxidative enzyme synthesis in the mitochondria enabling favorable oxidative conditions for the functioning of thyroid follicular cells (20).

Lack of any side effects or toxicity in all groups treated with metformin during the twelve-week experiment provides evidence of the safety of long-term metformin administration in rats. The animals in all groups gained appropriate weight, behaved normally during feeding and drinking and exhibited no signs of any pathology. This result is in line with a broad range of human clinical observations that confirm good tolerability of metformin in therapeutic doses and the rare occurrence of lactic acidosis in severely ill patients (3).

However, several limitations need addressing. First, the research has been performed only on healthy, male, and normoglycemic rats without studying any differences by sex in the mode of action of metformin on the thyroid. Thyroid disease reveals clear-cut sexual dimorphism in humans with women having approximately an eightfold higher incidence of autoimmune thyroid disease when compared to men (21). Further studies should be aimed at revealing if metformin protection also shows gender differences. Second, our research did not evaluate glucose, insulin levels and insulin sensitivity. Although the animals were healthy and normoglycemic, metformin could still produce changes. Third, we have not studied the possible mechanisms by which metformin can influence the thyroid functions at the molecular or molecular levels. Future studies should focus on the application of immunohistochemistry, western blotting and molecular biology.

Fourth, when designing the current study, the authors decided to conduct rather short experiment that lasted twelve weeks. Even though such period is long enough to show structural and biochemical changes, one can think of conducting more comprehensive long-term studies that could demonstrate whether metformin effect lasts for more than this period of time. Fifth, the current study was performed using conventional light microscopy, while one can assume

that electron microscopy could have provided better imaging of subcellular structures including mitochondria, endoplasmic reticulum and secretion granules.

Sixth, the current study has not assessed the immune function of the thyroid gland and the levels of antibodies for autoimmune thyroid disease. Thus, the assessment of anti-TPO and anti-thyroglobulin antibodies can show whether metformin exerts influence on thyroid autoimmunity.

The findings of the current study have very important clinical implications. Approximately, 20 percent of the global population nowadays has subclinical hypothyroidism which is characterized by elevated TSH and normal free thyroid hormones (22). Besides, thyroid diseases have their consequence and put the patients at higher risk of getting cardiovascular diseases, metabolic syndrome, and experience cognitive impairment in elderly. If it turns out that the metformin effect demonstrated in rats is applicable to human beings, then the treatment with metformin might achieve two results at once – stabilization of glycemia together with preservation of thyroid functions particularly among diabetic patients. Moreover, for the patients with thyroid diseases requiring levothyroxine application metformin during treatment may help achieve the optimal status of thyroid hormones and decrease the amount of required levothyroxine.

To sum up, the current experimental study offers the new data about metformin effects on the structure of the thyroid gland and hormonal homeostasis. Metformin treatment led to better organization of follicles as well as better morphology and development of cellular level. In addition, metformin increases colloid density and reduces the infiltration and damage of epithelial cells. The increase in thyroid hormones and decrease in TSH were both detected in blood.

References

- (1) Chiovato L, Magri F, Carlé A. Hypothyroidism in context: where we've been and where we're going. *Advances in Therapy*. 2020;37(12):4865-4883.
- (2) Saeedi P, Salpea P, Karuranga S. Diabetes epidemiology review of global burden: status and brief literature review. *Curr Diab Rep*. 2020;20(9):46.
- (3) Wang X, Bao W, Liu J, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. *Diabetes Care*. 2021;44(1):56-62.
- (4) Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. *J Clin Endocrinol Metab*. 2021;106(3):e1210-e1219.
- (5) Zhang Q, Chang W, Berezin A, et al. Metformin ameliorates diabetic nephropathy in mice with Akita diabetes. *Am J Nephrol*. 2022;53(1):29-43.
- (6) Ganong WF. *Review of Medical Physiology*. 26th ed. McGraw Hill; 2022.
- (7) Sawicka B, Karakus E, Schöfl C, et al. Pharmacological approaches to modulation of thyroid hormone metabolism. *Int J Mol Sci*. 2021;22(7):3546.
- (8) Wang H, Zhang B, Guo Q, et al. Oxidative stress in diabetic complications and the therapeutic potential of plant polyphenols. *Med Res Rev*. 2020;40(6):2475-2521.
- (9) Lin CL, Huang HC, Lin JK. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. *J Agric Food Chem*. 2021;69(18):5230-5241.
- (10) Lees PT, Latthe PM, Phipps RM. Animal models and translational research: a review of rodent models for preclinical endocrinology studies. *Front Endocrinol*. 2022;13:843625.
- (11) Padhy M, Karuppanan A, Gupta N, et al. Metformin and thyroid hormones: a systematic review of clinical evidence. *Curr Med Res Opin*. 2021;37(6):1063-1070.
- (12) Dohan O, De la Vieja A, Paroder V, et al. The sodium/iodide symporter and the thyroid peroxidase: biochemical characteristics and clinical relevance. *Exp Clin Endocrinol Diabetes*. 2022;130(4):227-242.

- (13) Garcia D, Shaw RJ. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. *Physiology*. 2023;38(2):145-161.
- (14) Marinò M, Latrofa F, Ito M, et al. Thymic stromal lymphopoietin in thyroid autoimmunity. *Front Endocrinol*. 2021;12:647408.
- (15) Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. *Nat Rev Endocrinol*. 2021;14(5):301-316.
- (16) Lee SJ, Seo YB, Kim KA, et al. Metformin attenuates lipopolysaccharide-induced NF- κ B signaling and inflammatory cytokine production in murine macrophages. *Immunopharmacol Immunotoxicol*. 2020;42(4):367-377.
- (17) Kim J, Guan KL. AMPK activation: mechanisms and therapeutic applications. *Exp Mol Med*. 2021;53(5):823-839.
- (18) Köhrle J. The selenoprotein thioredoxin reductase in endocrine tissues and its role in thyroid hormone metabolism. *Int J Mol Sci*. 2020;21(16):5804.
- (19) Li Q, Gao Z, Chen Y, et al. Metformin inhibits LPS-induced inflammatory response in macrophages through mTOR-independent mechanism. *Mediators Inflamm*. 2020;2020:9529040.
- (20) Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. *J Clin Endocrinol Metab*. 2022;107(10):2832-2854.
- (21) Weetman AP, Furmaniak J, Smith BR. Autoimmune thyroid disease: recent developments and new concepts. *J Autoimmun*. 2020;112:102480.
- (22) Surks MI, Hollowell JG. Age-specific distribution of serum thyroid stimulating hormone and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. *J Clin Endocrinol Metab*. 2023;92(12):4575-4582.